Alector Licenses AL050 Program to Roche's Genentech
MT newswire2026/10/05 11:2207:22 AM EDT, 10/05/2026 (MT Newswires) -- Alector (ALEC) said Monday it entered an exclusive global licensing agreement with Genentech, a Roche firm, for the development and commercialization of its AL050 program targeting Parkinson's disease. Under the deal, Alector said it will receive $100 million upfront and is eligible for up to $1.17 billion in development, regulatory and commercial milestones, as well as tiered royalties on net sales. Genentech will handle development, regulatory, manufacturing and commercialization globally, the company. Alector said it will retain ownership of its antibody blood-brain-barrier transport platform and rights to use it across its wholly owned pipeline.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Crypto prices
More
